Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB004 in Recurrent Glioblastoma
NCT03374943Phase 1Completed
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Dec 2017
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ifabotuzumab in glioblastoma (GBM), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Number of Participants With KB004 Treatment-Related Adverse Events. Started Dec 2017; status: completed.
02
Drugs
ifabotuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03374943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374943.